Investigational drug · Phase 2
GNOS-PV02
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HCC.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "GNOS-PV02"
First trial start
2020
Mar 1, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GNOS-PV02", any sponsor or status.
Conditions studied
As listed on its trial records.
- HCC
Largest trials
Live from ClinicalTrials.gov: studies naming "GNOS-PV02" as an intervention, largest first.
Geneos TherapeuticsIndustry
NCT07722741 · 90 participants (planned) · Start Sep 2026 · Primary completion Sep 2029
Drug: GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation; INO-9012 · For: HCC
Sites: Atlanta, Georgia; New Orleans, Louisiana; Baltimore, Maryland · 9 sites in all
- GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCCActive, not recruiting
Geneos TherapeuticsIndustry
NCT04251117 · 36 participants · Start Mar 1, 2020 · Primary completion Nov 29, 2024
Drug: GNOS-PV02; INO-9012 and 1 more · For: HCC
Sites: Baltimore, Maryland; New York, New York; Auckland, New Zealand
Newest research
PubMed records naming it or its code names, newest first.
- Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
Yarchoan M, Gane EJ, Marron TU, et al. · Nat Med 2024
- Personalized DNA Vaccine Tamps Down HCC.
· Cancer Discov 2022
Also in development for HCC
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- tirapazaminePhase 32 trials
Zhejiang Raygene Pharmaceuticals Co., Ltd · HCC, Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic
- INO-9012Phase 24 trials
Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma
- FOG-001Phase 21 trial
Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor
- PM1009Phase 21 trial
Biotheus Inc. · HCC, Liver Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.